ImaRx: A blood-clot attacker with sinking IPO hopes
ImaRx, a Tuscon, Ariz., biotech developing new ways to dissolve blood clots in the lungs, lowered its IPO sights and now expects to raise no more than $17.3 million in the offering. (Its latest SEC filing is here.) Late last month, the company had hoped to raise as much as $25.9 million by pricing its shares between $6.50 and $7.50 apiece.
ImaRx now expects to price its shares at $5 apiece. That will value the… Continue Reading
Ultrasound clot-buster Ekos raises $10M in debt
Ekos, a Bothell, Wash., maker of ultrasound-enhanced drug-delivery systems, raised $10 million in debt capital from Hercules Technology Growth Capital. The financing will support the sales and marketing of drug-delivery catheters that feature an ultrasound system designed to help drugs break up blood clots more quickly. Ekos launched its catheters in early 2006.
Ekos most recently raised $26 million in a third financing round led by Ascension Health Ventures, joined by new investors Oakwood Medical Investors… Continue Reading